Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 5
1964 4
1965 1
1966 4
1967 6
1968 6
1969 14
1970 16
1971 15
1972 15
1973 21
1974 19
1975 14
1976 19
1977 25
1978 22
1979 27
1980 25
1981 24
1982 20
1983 35
1984 83
1985 52
1986 43
1987 64
1988 115
1989 139
1990 159
1991 130
1992 193
1993 150
1994 147
1995 163
1996 150
1997 181
1998 150
1999 163
2000 210
2001 169
2002 222
2003 217
2004 197
2005 235
2006 215
2007 238
2008 258
2009 215
2010 225
2011 248
2012 281
2013 313
2014 306
2015 363
2016 352
2017 313
2018 355
2019 264
2020 337
2021 345
2022 373
2023 365
2024 301
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,607 results

Results by year

Filters applied: . Clear all
Page 1
Current best practice for bladder cancer: a narrative review of diagnostics and treatments.
Compérat E, Amin MB, Cathomas R, Choudhury A, De Santis M, Kamat A, Stenzl A, Thoeny HC, Witjes JA. Compérat E, et al. Lancet. 2022 Nov 12;400(10364):1712-1721. doi: 10.1016/S0140-6736(22)01188-6. Epub 2022 Sep 26. Lancet. 2022. PMID: 36174585 Review.
This Seminar presents the current best practice for the diagnosis and management of bladder cancer. The scope of this Seminar ranges from current challenges in pathology, such as the evolving histological and molecular classification of disease, to advances in personalised …
This Seminar presents the current best practice for the diagnosis and management of bladder cancer. The scope of this Seminar ranges …
Bladder Cancer: Current Challenges and Future Directions.
Dobruch J, Oszczudłowski M. Dobruch J, et al. Medicina (Kaunas). 2021 Jul 24;57(8):749. doi: 10.3390/medicina57080749. Medicina (Kaunas). 2021. PMID: 34440955 Free PMC article. Review.
Bladder cancer (BCa) is the most common malignancy of the urinary tract and one of the most prevalent cancers worldwide. ...Finally, improvements in molecular biology and our understanding of tumorigenesis open the era of personalized medicine in bladder canc …
Bladder cancer (BCa) is the most common malignancy of the urinary tract and one of the most prevalent cancers worldwide. ...Fi …
Diagnosis and Staging of Bladder Cancer.
Ahmadi H, Duddalwar V, Daneshmand S. Ahmadi H, et al. Hematol Oncol Clin North Am. 2021 Jun;35(3):531-541. doi: 10.1016/j.hoc.2021.02.004. Epub 2021 Apr 15. Hematol Oncol Clin North Am. 2021. PMID: 33958149 Review.
Cystoscopic examination remains the gold standard technique for initial diagnosis of bladder cancer (BCa). Despite significant progress in enhanced cystoscopic techniques, blue light cystoscopy and narrow band imaging are the only ones well supported by high-level evidence …
Cystoscopic examination remains the gold standard technique for initial diagnosis of bladder cancer (BCa). Despite significant progre …
Bladder cancer: epidemiology, staging and grading, and diagnosis.
Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM, Sesterhenn IA, Tachibana M, Weider J. Kirkali Z, et al. Urology. 2005 Dec;66(6 Suppl 1):4-34. doi: 10.1016/j.urology.2005.07.062. Urology. 2005. PMID: 16399414 Review.
At the other extreme, high-grade tumors have a high malignant potential associated with significant progression and cancer death rates. In the Western world, bladder cancer is the fourth most common malignancy in men and the eighth most common in women. ...Current s …
At the other extreme, high-grade tumors have a high malignant potential associated with significant progression and cancer death rate …
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes.
Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, Shariat SF, Zlotta AR, Boorjian SA. Dobruch J, et al. Eur Urol. 2016 Feb;69(2):300-10. doi: 10.1016/j.eururo.2015.08.037. Epub 2015 Sep 4. Eur Urol. 2016. PMID: 26346676 Review.
OBJECTIVE: To review the literature on potential biologic mechanisms underlying differential gender risk for bladder cancer, and evidence regarding gender disparities in bladder cancer presentation, management, and outcomes. ...Correspondingly, women have more advan …
OBJECTIVE: To review the literature on potential biologic mechanisms underlying differential gender risk for bladder cancer, and evid …
Bladder cancer: Present and future.
Martinez Rodriguez RH, Buisan Rueda O, Ibarz L. Martinez Rodriguez RH, et al. Med Clin (Barc). 2017 Nov 22;149(10):449-455. doi: 10.1016/j.medcli.2017.06.009. Epub 2017 Jul 21. Med Clin (Barc). 2017. PMID: 28736063 Review. English, Spanish.
Bladder cancer has a high incidence and involves high associated morbidity and mortality. ...
Bladder cancer has a high incidence and involves high associated morbidity and mortality. ...
Application of nanotechnology in the diagnosis and treatment of bladder cancer.
Xu Y, Luo C, Wang J, Chen L, Chen J, Chen T, Zeng Q. Xu Y, et al. J Nanobiotechnology. 2021 Nov 27;19(1):393. doi: 10.1186/s12951-021-01104-y. J Nanobiotechnology. 2021. PMID: 34838048 Free PMC article. Review.
Nanotechnology has been proposed as an effective method to improve theranosis efficiency for both non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). For example, gold nanoparticles (AuNPs) have been developed for simple, fast and s …
Nanotechnology has been proposed as an effective method to improve theranosis efficiency for both non-muscle invasive bladder cancer …
BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer.
Lidagoster S, Ben-David R, De Leon B, Sfakianos JP. Lidagoster S, et al. Curr Oncol. 2024 Feb 16;31(2):1063-1078. doi: 10.3390/curroncol31020079. Curr Oncol. 2024. PMID: 38392073 Free PMC article. Review.
Bladder cancer is a heterogeneous disease. Treatment decisions are mostly decided based on disease stage (non-muscle invasive or muscle invasive). ...The goal of intravesical therapy is to decrease the recurrence and/or progression of the tumor. In the current lands …
Bladder cancer is a heterogeneous disease. Treatment decisions are mostly decided based on disease stage (non-muscle invasive or musc …
Bladder cancer genomics.
Siracusano S, Rizzetto R, Porcaro AB. Siracusano S, et al. Urologia. 2020 May;87(2):49-56. doi: 10.1177/0391560319899011. Epub 2020 Jan 16. Urologia. 2020. PMID: 31942831 Review.
Until recently, the treatment of bladder cancer, for several years, was limited to surgery and to immunotherapy or chemotherapy. ...A future goal will be to combine treatment strategies of invasive bladder cancers according to their genetic mutational load defined b …
Until recently, the treatment of bladder cancer, for several years, was limited to surgery and to immunotherapy or chemotherapy. ...A …
Bladder cancer.
de Braud F, Maffezzini M, Vitale V, Bruzzi P, Gatta G, Hendry WF, Sternberg CN. de Braud F, et al. Crit Rev Oncol Hematol. 2002 Jan;41(1):89-106. doi: 10.1016/s1040-8428(01)00128-7. Crit Rev Oncol Hematol. 2002. PMID: 11796234 Review.
Bladder cancer is the second most frequent tumour of the urogenital tract. Tobacco smoke has been shown to increase the risk of bladder cancer two- to fivefold as well as the exposure to metabolites of aniline dyes and other aromatic amines. Seventy-five per cent of …
Bladder cancer is the second most frequent tumour of the urogenital tract. Tobacco smoke has been shown to increase the risk of bl …
8,607 results